Phase 1 Randomized Controlled Trial of the Safety and Immunogenicity of the SARS-CoV-2 (Omicron BA.5) mRNA-CR-04 Vaccine in Adults 18–49 Years of Age
The investigational mRNA-CR-04 vaccine was generally well tolerated, and all doses induced a robust immune response against the encoded antigen at doses ranging between 3 and 100 µg. Further investigation of potential vaccine candidates using this novel mRNA platform is warranted.
Authors
- Kavita Aggarwal (ORCID: https://orcid.org/0009-0007-6650-1659)
- Giulietta Maruggi (ORCID: https://orcid.org/0000-0002-3877-3434)
- Hema Sharma (ORCID: https://orcid.org/0000-0001-6396-2344)
- Yingmei Xi
- Morris Loughrey (ORCID: https://orcid.org/0009-0009-1174-1799)
- Abdi Naficy (ORCID: https://orcid.org/0000-0002-1076-5280)
- Bach-Yen Nguyen (ORCID: https://orcid.org/0009-0005-8008-5247)
- Daniel Brüne
- Mireille Venken (ORCID: https://orcid.org/0009-0005-2909-9547)
Institutions
- GlaxoSmithKline (Belgium) (BE)
- Applied Research (United States) (US)
- GlaxoSmithKline (United States) (US)
- Institut de Recherche Vaccinale (FR)
- Illinois CancerCare (US)
- Biostatistical Consulting (United States) (US)
- Global Vaccines (United States) (US)
- Massachusetts Institute of Technology (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-11-26
- DOI
- https://doi.org/10.1093/ofid/ofaf689
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00